• Our vision is to balance mother nature and human engineering to discover and develop innovative antibody therapeutics

Leadership Team
Peter (Peizhi) Luo, Ph.D.
Co-founder and CEO

Dr. Peter (Peizhi) Luo, the founder and Chief Executive Officer of Adagene, is an experienced entrepreneur passionate on devising a sustainable biotechnology business strategy by leveraging the industry’s most advanced technology and intellectual property for novel product development. Dr. Luo has focused on studying the fundamental mechanisms of protein folding and design principle, and particularly by computational and experimental approaches for the last 20 years.
Prior to founding Adagene, Dr. Luo was the Co-founder, Chief Technology Officer, President and Director of Abmaxis Inc, which was acquired by Merck & Co. in 2006. Dr. Luo then served as Director of Biologics Technology at Merck. Prior to Abmaxis, Dr. Luo served as the first lead scientist in computational protein design and protein laboratory at Xencor.
Dr. Luo completed his postdoctoral research in protein folding with Dr. Robert L. Baldwin at Stanford University. He received his Ph.D. in chemistry under the guidance of Dr. David G. Lynn at The University of Chicago, M.S. degree in applied physics from The Institute of High Energy Physics of the Chinese Academy of Sciences, and B.S. degree in applied chemistry from Peking University.

Felix (Fangyong) Du, Ph.D.
SVP, Chief Technology Officer

Dr. Felix (Fangyong) Du is the Sr Vice President and Chief Scientist of Technology Development at Adagene. He has over 20 years of experience in biological research and discovery, and has published numerous peer-reviewed articles, including original articles in world-renowned scientific journals such as Nature and Science. His discoveries were featured on the cover of Nature and critically reviewed with high praise by prominent scientists in the field.
Before joining Adagene, Dr. Du worked at Affomix, a biotech startup by Yale professors that specializes in high throughput discovery of antibodies against human proteome. He created an innovative technology platform for high throughput preparation and oriented presentation of antigens. After acquisition of Affomix by Illumina Inc., Dr. Du continued to develop new technologies in protein and nucleic acid chemistry.
Dr. Du completed his postdoctoral research with Dr. Jorge Galan at Yale University, received his Ph.D. under the guidance of Dr. Alex Varshavsky at the California Institute of Technology, and obtained his B.S. and M.S. degrees from Peking University.

Raymond Tam, M.B.A
Chief Financial Officer

Mr. Raymond Tam Man Kin (“Mr. Tam”) is the Chief Financial Officer of Adagene. He has over 20 years of management experience in finance and banking across Asia Pacific.
Prior to Adagene, Mr. Tam served as Chief Financial Officer of different corporations including AgenTus Therapeutics, Inc., Beijing Gas Blue Sky Holdings Limited (a company listed on the Stock Exchange of Hong Kong), and China Regenerative Medicine International Limited (a company listed on the Stock Exchange of Hong Kong). Mr. Tam also served as Project Director of Mineralogy Pty Limited and Chief Financial Officer of Resourcehouse Limited, both of which are Australian mining companies. Further, he held various management positions with J.P. Morgan and HSBC during 1999 to 2010.
Mr. Tam obtained an Executive Master of Business Administration degree from the University of Western Ontario in Canada in 2005, a Master of Practising Accounting degree from the Monash University in Australia in 2001 and a Bachelor of Civil & Resources Engineering (with First Class Honors) degree from the University of Auckland in New Zealand in 1998.
Mr. Tam is a Fellow of CPA Australia, a member of the American Institute of Certified Public Accountants and the Hong Kong Institute of Certified Public Accountants. He is also a CFA and FRM charter-holder.

Yan Li, M.B.A
SVP, Bioinformatics and Information Technology

Ms. Yan Li is the Vice President of Bioinformatics and Information Technology at Adagene. She has over 15 years of experience in software development, with more than 10 years focused on the development of informatics software tools for antibody library design and analysis.
Prior to joining Adagene, Ms. Li served as the Senior Software Engineer and Applications Scientist at Abmaxis from Nov 2001 to May 2006. She developed the software platform for the company’s proprietary AISIM technology, and designed many antibody libraries for in-house pipeline development and business partners. Following the acquisition of Abmaxis by Merck & Co, Ms. Li worked at Merck from May 2006 to Dec 2010. She received the Merck Award for Excellence in "Innovative Technologies” with the team, and a Special Award for her contribution.
Before her time at Abmaxis, Ms. Li served as a software engineer at Easyware Software, and also as a system analyst and product manager at Singapore Telecom. Ms. Li received her BSE in Information Science from East China University of Science and Technology, and her M.B.A. from Santa Clara University with Beta Gamma Sigma honor. She is an inventor of many US and international patents.

Kristine (Xiaohong) She
SVP, Head of Clinical Operations

Ms. Kristine (Xiaohong) She serves as the Vice President of Operations at Adagene. She has over 20 years of laboratory experience in America’s most renown laboratories, completing multiple projects in molecular biology and immunology at the labs of University of Chicago, the Genome Center at Stanford University, neurological animal studies at Stanford Palo Alto Veteran’s Hospital, and cloning and functional screening of cDNA libraries at Caltech. Her work has been published in Nature, Science, Biotechnology, among many other notable publications. From these projects, Ms. She has gained extensive operational and management experience, as she often led her coworkers in laboratory and experimental work.
Ms. She received her M.S. degree from the Institute of Microbiology of the Chinese Academy of Sciences, and her B.S. degree from Wuhan University.

Alexander Goergen
Head of Business Development

Alexander Goergen is the Executive Director of business development and head of licensing at Adagene. He has extensive experience in partnering and strategic planning, and is focused on fostering synergistic relationships in the pharmaceutical and biotech industry for the purpose of advancing human healthcare. Prior to joining Adagene, Alexander spent several years in business development for Catalent Pharma Solutions Biologics Division.
Alexander completed many licensing, manufacturing, and cell line development programs both domestically and internationally. Alexander was also in charge of managing a relationship with one of Catalent’s key global strategic accounts prior to joining Adagene. Before joining Catalent, Alexander has worked in various roles at the International AIDS Vaccine Initiative, Covance , and TRC. Alexander holds an M.S. from the School of Medicine and Public Health at the University of Wisconsin-Madison. He completed his undergraduate work at Lafayette College.

Ron (Yuren) Wang, Ph.D.
Head of Portfolio Management

Dr. Wang has over 20 years of drug discovery and development experience in large pharmaceutical and biotech companies, making significant contributions to the scientific development of various drugs. During his career, he has led or integrally participated in over 20 projects from novel target validation, drug discovery, and biomarker strategy to preclinical candidates.
Prior to joining Adagene, Dr. Wang served as Vice President of R&D research for Jemincare Therapeutics (USA), responsible for the scientific evaluation of projects, in-licensing and portfolio management. Before that, he was the Senior Director of Business Development in Reaction Biology Corporation (RBC), where he led custom service in drug discovery of protein kinases and cancer epigenetic areas. Dr. Wang was also project leaders in metabolic disease of Bristol Myers Squibb, and Wyeth Neuroscience Research (now, owned by Pfizer).
Dr. Wang received his PhD in Molecular and Cellular Biology from the University of Pennsylvania and completed his postdoctoral training in molecular pharmacology at Dr. David Manning’s laboratory at the University of Pennsylvania. He has published more than 30 research papers in peer-reviewed journals and is the inventor of multiple patents.

Leadership Team
  1. Peter Luo
    Co-founder and CEO
  2. Felix Du
    SVP, Chief Technology Officer
  3. Raymond Tam
    Chief Financial Officer
  4. Yan Li
    SVP, Bioinformatics and Information Technology
  5. Kristine She
    SVP, Head of Clinical Operations
  6. Alexander Goergen
    Head of Business Development
  7. Ron Wang
    Head of Portfolio Management
  • Peter (Peizhi) Luo, Ph.D.

    Dr. Peter (Peizhi) Luo, the founder and Chief Executive Officer of Adagene, is an experienced entrepreneur passionate on devising a sustainable biotechnology business strategy by leveraging the industry’s most advanced technology and intellectual property for novel product development. Dr. Luo has focused on studying the fundamental mechanisms of protein folding and design principle, and particularly by computational and experimental approaches for the last 20 years.
    Prior to founding Adagene, Dr. Luo was the Co-founder, Chief Technology Officer, President and Director of Abmaxis Inc, which was acquired by Merck & Co. in 2006. Dr. Luo then served as Director of Biologics Technology at Merck. Prior to Abmaxis, Dr. Luo served as the first lead scientist in computational protein design and protein laboratory at Xencor.
    Dr. Luo completed his postdoctoral research in protein folding with Dr. Robert L. Baldwin at Stanford University. He received his Ph.D. in chemistry under the guidance of Dr. David G. Lynn at The University of Chicago, M.S. degree in applied physics from The Institute of High Energy Physics of the Chinese Academy of Sciences, and B.S. degree in applied chemistry from Peking University.

  • Felix (Fangyong) Du, Ph.D.

    Dr. Felix (Fangyong) Du is the Sr Vice President and Chief Scientist of Technology Development at Adagene. He has over 20 years of experience in biological research and discovery, and has published numerous peer-reviewed articles, including original articles in world-renowned scientific journals such as Nature and Science. His discoveries were featured on the cover of Nature and critically reviewed with high praise by prominent scientists in the field.
    Before joining Adagene, Dr. Du worked at Affomix, a biotech startup by Yale professors that specializes in high throughput discovery of antibodies against human proteome. He created an innovative technology platform for high throughput preparation and oriented presentation of antigens. After acquisition of Affomix by Illumina Inc., Dr. Du continued to develop new technologies in protein and nucleic acid chemistry.
    Dr. Du completed his postdoctoral research with Dr. Jorge Galan at Yale University, received his Ph.D. under the guidance of Dr. Alex Varshavsky at the California Institute of Technology, and obtained his B.S. and M.S. degrees from Peking University.

  • Raymond Tam, M.B.A

    Mr. Raymond Tam Man Kin (“Mr. Tam”) is the Chief Financial Officer of Adagene. He has over 20 years of management experience in finance and banking across Asia Pacific.
    Prior to Adagene, Mr. Tam served as Chief Financial Officer of different corporations including AgenTus Therapeutics, Inc., Beijing Gas Blue Sky Holdings Limited (a company listed on the Stock Exchange of Hong Kong), and China Regenerative Medicine International Limited (a company listed on the Stock Exchange of Hong Kong). Mr. Tam also served as Project Director of Mineralogy Pty Limited and Chief Financial Officer of Resourcehouse Limited, both of which are Australian mining companies. Further, he held various management positions with J.P. Morgan and HSBC during 1999 to 2010.
    Mr. Tam obtained an Executive Master of Business Administration degree from the University of Western Ontario in Canada in 2005, a Master of Practising Accounting degree from the Monash University in Australia in 2001 and a Bachelor of Civil & Resources Engineering (with First Class Honors) degree from the University of Auckland in New Zealand in 1998.
    Mr. Tam is a Fellow of CPA Australia, a member of the American Institute of Certified Public Accountants and the Hong Kong Institute of Certified Public Accountants. He is also a CFA and FRM charter-holder.

  • Yan Li, M.B.A

    Ms. Yan Li is the Vice President of Bioinformatics and Information Technology at Adagene. She has over 15 years of experience in software development, with more than 10 years focused on the development of informatics software tools for antibody library design and analysis.
    Prior to joining Adagene, Ms. Li served as the Senior Software Engineer and Applications Scientist at Abmaxis from Nov 2001 to May 2006. She developed the software platform for the company’s proprietary AISIM technology, and designed many antibody libraries for in-house pipeline development and business partners. Following the acquisition of Abmaxis by Merck & Co, Ms. Li worked at Merck from May 2006 to Dec 2010. She received the Merck Award for Excellence in "Innovative Technologies” with the team, and a Special Award for her contribution.
    Before her time at Abmaxis, Ms. Li served as a software engineer at Easyware Software, and also as a system analyst and product manager at Singapore Telecom.
    Ms. Li received her BSE in Information Science from East China University of Science and Technology, and her M.B.A. from Santa Clara University with Beta Gamma Sigma honor. She is an inventor of many US and international patents.

  • Kristine (Xiaohong) She

    Ms. Kristine (Xiaohong) She serves as the Vice President of Operations at Adagene. She has over 20 years of laboratory experience in America’s most renown laboratories, completing multiple projects in molecular biology and immunology at the labs of University of Chicago, the Genome Center at Stanford University, neurological animal studies at Stanford Palo Alto Veteran’s Hospital, and cloning and functional screening of cDNA libraries at Caltech. Her work has been published in Nature, Science, Biotechnology, among many other notable publications. From these projects, Ms. She has gained extensive operational and management experience, as she often led her coworkers in laboratory and experimental work.
    Ms. She received her M.S. degree from the Institute of Microbiology of the Chinese Academy of Sciences, and her B.S. degree from Wuhan University.

  • Alexander Goergen

    Alexander Goergen is the Executive Director of business development and head of licensing at Adagene. He has extensive experience in partnering and strategic planning, and is focused on fostering synergistic relationships in the pharmaceutical and biotech industry for the purpose of advancing human healthcare. Prior to joining Adagene, Alexander spent several years in business development for Catalent Pharma Solutions Biologics Division.
    Alexander completed many licensing, manufacturing, and cell line development programs both domestically and internationally. Alexander was also in charge of managing a relationship with one of Catalent’s key global strategic accounts prior to joining Adagene. Before joining Catalent, Alexander has worked in various roles at the International AIDS Vaccine Initiative, Covance , and TRC. Alexander holds an M.S. from the School of Medicine and Public Health at the University of Wisconsin-Madison. He completed his undergraduate work at Lafayette College.

  • Ron (Yuren) Wang, Ph.D.

    Dr. Wang has over 20 years of drug discovery and development experience in large pharmaceutical and biotech companies, making significant contributions to the scientific development of various drugs. During his career, he has led or integrally participated in over 20 projects from novel target validation, drug discovery, and biomarker strategy to preclinical candidates.
    Prior to joining Adagene, Dr. Wang served as Vice President of R&D research for Jemincare Therapeutics (USA), responsible for the scientific evaluation of projects, in-licensing and portfolio management. Before that, he was the Senior Director of Business Development in Reaction Biology Corporation (RBC), where he led custom service in drug discovery of protein kinases and cancer epigenetic areas. Dr. Wang was also project leaders in metabolic disease of Bristol Myers Squibb, and Wyeth Neuroscience Research (now, owned by Pfizer).
    Dr. Wang received his PhD in Molecular and Cellular Biology from the University of Pennsylvania and completed his postdoctoral training in molecular pharmacology at Dr. David Manning’s laboratory at the University of Pennsylvania. He has published more than 30 research papers in peer-reviewed journals and is the inventor of multiple patents.

Board Of Directors
Peter(Peizhi) Luo, Ph.D.
Cofounder, Chairman and CEO, Adagene

Dr. Peter (Peizhi) Luo, the founder and Chief Executive Officer of Adagene, a clinical stage biotech company with innovative antibody discovery and engineering technologies. By utilizing its proprietary Dynamic Precision Library Platform (DPL) and SAFEbody™ technologies, Adagene is showcasing its exceptional antibody engineering capabilities building franchises of second and third-generation antibody products.
Prior to founding Adagene, Dr. Luo was the Chief Technology Officer of Abmaxis Inc., a wholly owned subsidiary of Merck & Co., and Director of Biologics Technology at Merck & Co., Inc. Dr. Luo was the Cofounder, Chief Technology Officer, President and a Board Director of Abmaxis Inc, which was acquired by Merck in 2006. Prior to Abmaxis, Dr. Luo served as the first lead scientist in computational protein design and protein laboratory at Xencor. Dr. Luo has focused on studying the fundamental mechanisms of protein folding and design principle, and antibody in particular by computational and experimental approaches for the last 20 years.
Dr. Luo completed his postdoctoral research in protein folding with Dr. Robert L. Baldwin at Stanford University. He received his Ph.D. in chemistry under the guidance of Dr. David G. Lynn at The University of Chicago, M.S. degree in applied physics from The Institute of High Energy Physics of the Chinese Academy of Sciences, and B.S. degree in applied chemistry from Peking University.

Daniel Auerbach, M.B.A.
Biography Managing Partner, Asia, Eight Roads

Daniel Auerbach is the Managing Partner of Eight Roads Capital Advisors (Hong Kong) Limited, the Asia Pacific Private Equity and Venture investing arm of FIL Limited (formerly Fidelity International Ltd), an affiliate of one of the World’s largest, independent, privately held money management firms. Mr. Auerbach has held this role since 1994, representing a significant component of his 30 years in Asia as an early pioneer and leader in the Development of Asia’s Private Equity industry. Through his business involvement Mr. Auerbach is associated with the establishment of some of the region’s most successful independent businesses in the areas of the internet, IT out-sourcing, software, media, telecommunications, education, business-process outsourcing, infrastructure, health care services, bio-chemistry research services, bio-technology and bio-pharma development and distribution. Mr. Auerbach has held key board roles with a multitude of companies, including the Alibaba Group, Wuxi Pharmatech, AsiaInfo, Asia Renal Care and several others. He continues to serve on a number of Boards of Asia’s leading emerging businesses. Mr. Auerbach is a member of Fidelity’s Senior Leadership throughout Asia Pacific.
Prior to 1994 for a period spanning over 7 years, Mr. Auerbach was a Partner at Arral and Partners, one of Asia’s first independent private equity firms, based in Hong Kong. Among other things Arral and Partners was the founding investor in the Aman Resorts Hotel Group, where Mr. Auerbach played a key role in its global development since its establishment in 1987. From 1980-1985 Mr. Auerbach was based in Boston working at Fidelity as an equity analyst and portfolio management assistant to Peter Lynch, the manager of the Fidelity Magellan Fund.
Apart from his business activities, Mr. Auerbach is a member of various international and local businesses, philanthropic and civic organisations. He is a Trustee of Hong Kong‘s World Wildlife Fund; A Trustee of the Hong Kong Plastic Oceans Foundation; A member of the Board of Overseers at the Morningside College, Asia’s first liberal arts college based in Hong Kong; A member of the Presidential Advisory Board of the Berklee College of Music in Boston. Mr. Auerbach also plays a primary role in leading a multitude of initiatives on behalf of the Fidelity Charitable Foundations.
In 2000, Mr. Auerbach was nominated by the World Economic Forum as one of its Young Global Leaders.
Mr. Auerbach holds a B.A from Dartmouth College (1980) in Economics and Foreign Languages and an M.B.A. from The Harvard Business School in Boston. Mr. Auerbach lives in Hong Kong.

Chong Xu, Ph.D., M.B.A.
Principal, F-Prime Capital

Chong is a Principal at F-Prime Capital. He focuses primarily on biopharmaceutical and medical technology sectors and works closely with the Eight Roads Ventures Asia team to manage portfolio companies and new investment opportunities in the U.S. and in China, such as Innovent Biologics and Semma Therapeutics, among others. Prior to joining F-Prime in 2015, Chong was an associate in McKinsey and Company’s Boston office, a hedge fund healthcare equity analyst with Massif Partners and Affirmed Healthcare, and a researcher focusing on developmental neurobiology at Temasek Life Sciences Laboratory in Singapore.
Chong holds a Ph.D. in Cell Biology from University of Virginia and a MBA from Darden School of Business, University of Virginia. He received his B.S. in biology from Zhejiang University, China.

Lynn Yang, M.B.A.
Managing Director, Sequoia Capital China

Lynn Yang joined Sequoia Capital as a managing director in May 2015 where she focuses on healthcare investment. Prior to joining Sequoia Capital, Ms. Yang worked at Legend Capital as a member of the healthcare team. She has participated in investments in different sectors of the healthcare industry such as Burning Rock, Cstone (2616.HK), JW Therapeutics,Grail, Hongkong Asia Medical etc. Before starting in venture capital, Ms. Yang worked as a business development manager at Johnson & Johnson and a product manager at GE Healthcare.
Ms. Yang holds an MBA from Duke University and a MS in Clinical Science from Huazhong Technology University.

Yu Miao
Executive Director, GP Healthcare Capital

Yu Miao is the Executive Director of GP Healthcare Captial Co.,Ltd, and he is mainly responsible for equity investment focusing on healthcare industry. Since joining GP Healthcare Capital in 2015, he has led investment in CF PharmTech, Adagene, MicuRx, Eureka Therapeutics, Sinovision, Transthera, etc. Prior to joining GP Healthcare Captial, Yu Miao worked at Eli Lilly & Co. and Oriza Seed Fund Management Co., Ltd.
Mr. Miao hold MS in Pharmaceutical Science in Northeastern University.

Lefei Sun
Managing Director, Head of China Healthcare, General Atlantic

Lefei Sun is a Managing Director and Head of Healthcare for General Atlantic’s China region. Before joining the firm in 2018, Lefei was the Founding Partner of HuaTai Healthcare Investment Fund. Prior to that, Lefei was lead healthcare analyst from Credit Suisse, founding team member of OrbiMed’s Asia fund, and a management consultant from McKinsey & Company, all in the healthcare sector. He has rich experiences in both private and public healthcare investment market and played instrumental role in the investment of many healthcare leading companies such as Mindray Medical in Medtech and Asia Medical (Wuhan Asia Heart Hospital) in healthcare services.
Mr.Sun hold M.A. in Neuroscience from The Johns Hopkins University Medical School and a B.S. in Mathematics and Physics from Tsinghua University.

Board Of Directors
  1. Peter Luo
  2. Daniel Auerbach
  3. Chong Xu
  4. Lynn Yang
  5. Yu Miao
  6. Lefei Sun
  • Peter(Peizhi) Luo, Ph.D.
    Cofounder, Chairman and CEO, Adagene

    Dr. Peter (Peizhi) Luo, the founder and Chief Executive Officer of Adagene, a clinical stage biotech company with innovative antibody discovery and engineering technologies. By utilizing its proprietary Dynamic Precision Library Platform (DPL) and SAFEbody™ technologies, Adagene is showcasing its exceptional antibody engineering capabilities building franchises of second and third-generation antibody products.
    Prior to founding Adagene, Dr. Luo was the Chief Technology Officer of Abmaxis Inc., a wholly owned subsidiary of Merck & Co., and Director of Biologics Technology at Merck & Co., Inc. Dr. Luo was the Cofounder, Chief Technology Officer, President and a Board Director of Abmaxis Inc, which was acquired by Merck in 2006. Prior to Abmaxis, Dr. Luo served as the first lead scientist in computational protein design and protein laboratory at Xencor. Dr. Luo has focused on studying the fundamental mechanisms of protein folding and design principle, and antibody in particular by computational and experimental approaches for the last 20 years.
    Dr. Luo completed his postdoctoral research in protein folding with Dr. Robert L. Baldwin at Stanford University. He received his Ph.D. in chemistry under the guidance of Dr. David G. Lynn at The University of Chicago, M.S. degree in applied physics from The Institute of High Energy Physics of the Chinese Academy of Sciences, and B.S. degree in applied chemistry from Peking University.

  • Daniel Auerbach, M.B.A.
    Biography Managing Partner, Asia, Eight Roads

    Daniel Auerbach is the Managing Partner of Eight Roads Capital Advisors (Hong Kong) Limited, the Asia Pacific Private Equity and Venture investing arm of FIL Limited (formerly Fidelity International Ltd), an affiliate of one of the World’s largest, independent, privately held money management firms.
    Mr. Auerbach has held this role since 1994, representing a significant component of his 30 years in Asia as an early pioneer and leader in the Development of Asia’s Private Equity industry. Through his business involvement Mr. Auerbach is associated with the establishment of some of the region’s most successful independent businesses in the areas of the internet, IT out-sourcing, software, media, telecommunications, education, business-process outsourcing, infrastructure, health care services, bio-chemistry research services, bio-technology and bio-pharma development and distribution. Mr. Auerbach has held key board roles with a multitude of companies, including the Alibaba Group, Wuxi Pharmatech, AsiaInfo, Asia Renal Care and several others. He continues to serve on a number of Boards of Asia’s leading emerging businesses. Mr. Auerbach is a member of Fidelity’s Senior Leadership throughout Asia Pacific.
    Prior to 1994 for a period spanning over 7 years, Mr. Auerbach was a Partner at Arral and Partners, one of Asia’s first independent private equity firms, based in Hong Kong. Among other things Arral and Partners was the founding investor in the Aman Resorts Hotel Group, where Mr. Auerbach played a key role in its global development since its establishment in 1987. From 1980-1985 Mr. Auerbach was based in Boston working at Fidelity as an equity analyst and portfolio management assistant to Peter Lynch, the manager of the Fidelity Magellan Fund.
    Apart from his business activities, Mr. Auerbach is a member of various international and local businesses, philanthropic and civic organisations. He is a Trustee of Hong Kong‘s World Wildlife Fund; A Trustee of the Hong Kong Plastic Oceans Foundation; A member of the Board of Overseers at the Morningside College, Asia’s first liberal arts college based in Hong Kong; A member of the Presidential Advisory Board of the Berklee College of Music in Boston. Mr. Auerbach also plays a primary role in leading a multitude of initiatives on behalf of the Fidelity Charitable Foundations.
    In 2000, Mr. Auerbach was nominated by the World Economic Forum as one of its Young Global Leaders.
    Mr. Auerbach holds a B.A from Dartmouth College (1980) in Economics and Foreign Languages and an M.B.A. from The Harvard Business School in Boston. Mr. Auerbach lives in Hong Kong.

  • Chong Xu, Ph.D., M.B.A.
    Principal, F-Prime Capital

    Chong is a Principal at F-Prime Capital. He focuses primarily on biopharmaceutical and medical technology sectors and works closely with the Eight Roads Ventures Asia team to manage portfolio companies and new investment opportunities in the U.S. and in China, such as Innovent Biologics and Semma Therapeutics, among others. Prior to joining F-Prime in 2015, Chong was an associate in McKinsey and Company’s Boston office, a hedge fund healthcare equity analyst with Massif Partners and Affirmed Healthcare, and a researcher focusing on developmental neurobiology at Temasek Life Sciences Laboratory in Singapore.
    Chong holds a Ph.D. in Cell Biology from University of Virginia and a MBA from Darden School of Business, University of Virginia. He received his B.S. in biology from Zhejiang University, China.

  • Lynn Yang, M.B.A.
    Managing Director, Sequoia Capital China

    Lynn Yang joined Sequoia Capital as a managing director in May 2015 where she focuses on healthcare investment. Prior to joining Sequoia Capital, Ms. Yang worked at Legend Capital as a member of the healthcare team. She has participated in investments in different sectors of the healthcare industry such as Burning Rock, Cstone (2616.HK), JW Therapeutics,Grail, Hongkong Asia Medical etc. Before starting in venture capital, Ms. Yang worked as a business development manager at Johnson & Johnson and a product manager at GE Healthcare.
    Ms. Yang holds an MBA from Duke University and a MS in Clinical Science from Huazhong Technology University.

  • Yu Miao
    Executive Director, GP Healthcare Capital

    Yu Miao is the Executive Director of GP Healthcare Captial Co.,Ltd, and he is mainly responsible for equity investment focusing on healthcare industry. Since joining GP Healthcare Capital in 2015, he has led investment in CF PharmTech, Adagene, MicuRx, Eureka Therapeutics, Sinovision, Transthera, etc. Prior to joining GP Healthcare Captial, Yu Miao worked at Eli Lilly & Co. and Oriza Seed Fund Management Co., Ltd.
    Mr. Miao hold MS in Pharmaceutical Science in Northeastern University.

  • Lefei Sun
    Managing Director, Head of China Healthcare, General Atlantic

    Lefei Sun is a Managing Director and Head of Healthcare for General Atlantic’s China region. Before joining the firm in 2018, Lefei was the Founding Partner of HuaTai Healthcare Investment Fund. Prior to that, Lefei was lead healthcare analyst from Credit Suisse, founding team member of OrbiMed’s Asia fund, and a management consultant from McKinsey & Company, all in the healthcare sector. He has rich experiences in both private and public healthcare investment market and played instrumental role in the investment of many healthcare leading companies such as Mindray Medical in Medtech and Asia Medical (Wuhan Asia Heart Hospital) in healthcare services.
    Mr.Sun hold M.A. in Neuroscience from The Johns Hopkins University Medical School and a B.S. in Mathematics and Physics from Tsinghua University.

INVESTORS
F-Prime Capital Partners
Learn more >

Fidelity Investments was founded in 1946 and grew from a single mutual fund into one of the largest asset management firms in the world, with over $2 trillion in assets under management. For the last forty years, our venture capital group has had the privilege of backing other great entrepreneurs as they built ground-breaking companies in technology and life sciences, including Atari, MCI, ROLM Corp., Alibaba, Ironwood Pharmaceuticals, and Ultragenyx.

fprimecapital.com
Eight Roads Ventures
Learn more >

Eight Roads Ventures (formerly Fidelity Growth Partners) is the venture arm of Eight Roads, the proprietary investment arm of Fidelity International Limited. As a private venture capital investor, Eight Roads Ventures is dedicated to long-term investment approach on ventures specialized in Healthcare and Biosciences, and Technology. A strong track record includes investments in Alibaba, WuXi PharmaTech, Innovent, Hua Medicine, Hile, etc.

eightroads.com
WuXi AppTec
Learn more >

WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. As an innovation-driven and customer-focused company, WuXi AppTec helps our partners improve the productivity of advancing healthcare products through cost-effective and efficient solutions. With industry-leading capabilities such as R&D and manufacturing for small molecule drugs, cell and gene therapies, and testing for medical devices, WuXi AppTec’s open-access platform is enabling more than 3,900 collaborators from over 30 countries to improve the health of those in need – and to realize our vision that "every drug can be made and every disease can be treated."

www.wuxiapptec.com
GP Healthcare Capital
Learn more >

GP Healthcare Capital, a subsidiary fund of GP Capital, is a professionally managed private equity fund which invests in disruptive technology and products within the healthcare industry. Our mission is to provide capital to innovative organizations with visionary leadership teams who are challenging the status quo of medicine as it is practiced globally. We work closely with entrepreneurs to achieve our vision of a "Value Discoverer" and "Value Creator".

www.gpcapital.com.cn
New World TMT Ltd
Learn more >

New World TMT Ltd (NWTMT) is the telecom, media and technology business management arm of the New World Group, one of Hong Kong's blue chip conglomerates. Comprising three operational areas - Telecom, Media and Technology - NWTMT invests and operates in innovative telemedia enterprises in China and the Asia Pacific region.
New World TMT is positioned to benefit from regional liberalization initiatives and technological advancement. By way of providing management support, strategic partnerships and capital, the company aims to maximize returns and create shareholder value for a portfolio of enterprises in which NWTMT has significant equity interest.

www.nwtmt.com
Sequoia China
Learn more >

The Sequoia team helps daring founders build legendary companies. In partnering with Sequoia, companies benefit from our unmatched community and the lessons we’ve learned over 46 years working with Apple, Cisco, Oracle, Google, Alibaba, Airbnb and JD.com among many others. As “The Entrepreneurs Behind The Entrepreneurs”, Sequoia China focuses on four sectors: TMT, healthcare, consumer/service, and industrial technology. Over the past 13 years we’ve had the privilege of working with more than 500 companies in China.

www.sequoiacap.com/china/en
General Atlantic
Learn more >

General Atlantic is a leading global growth equity firm providing capital and strategic support for growth companies. Established in 1980, General Atlantic combines a collaborative global approach, sector specific expertise, a long-term investment horizon and a deep understanding of growth drivers to partner with great entrepreneurs and management teams to build exceptional businesses worldwide. General Atlantic has more than 150 investment professionals based in New York, Amsterdam, Beijing, Greenwich, Hong Kong, Jakarta, London, Mexico City, Mumbai, Munich, Palo Alto, São Paulo, Shanghai, and Singapore. For more information on General Atlantic.

www.generalatlantic.com
INVESTORS
    • F-Prime Capital Partners

      Fidelity Investments was founded in 1946 and grew from a single mutual fund into one of the largest asset management firms in the world, with over $2 trillion in assets under management. For the last forty years, our venture capital group has had the privilege of backing other great entrepreneurs as they built ground-breaking companies in technology and life sciences, including Atari, MCI, ROLM Corp., Alibaba, Ironwood Pharmaceuticals, and Ultragenyx.

    • Eight Roads Ventures

      Eight Roads Ventures (formerly Fidelity Growth Partners) is the venture arm of Eight Roads, the proprietary investment arm of Fidelity International Limited. As a private venture capital investor, Eight Roads Ventures is dedicated to long-term investment approach on ventures specialized in Healthcare and Biosciences, and Technology. A strong track record includes investments in Alibaba, WuXi PharmaTech, Innovent, Hua Medicine, Hile, etc.

    • WuXi AppTec

      WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. As an innovation-driven and customer-focused company, WuXi AppTec helps our partners improve the productivity of advancing healthcare products through cost-effective and efficient solutions. With industry-leading capabilities such as R&D and manufacturing for small molecule drugs, cell and gene therapies, and testing for medical devices, WuXi AppTec’s open-access platform is enabling more than 3,900 collaborators from over 30 countries to improve the health of those in need – and to realize our vision that "every drug can be made and every disease can be treated."

    • GP Healthcare Capital

      GP Healthcare Capital, a subsidiary fund of GP Capital, is a professionally managed private equity fund which invests in disruptive technology and products within the healthcare industry. Our mission is to provide capital to innovative organizations with visionary leadership teams who are challenging the status quo of medicine as it is practiced globally. We work closely with entrepreneurs to achieve our vision of a "Value Discoverer" and "Value Creator".

    • New World TMT Ltd

      New World TMT Ltd (NWTMT) is the telecom, media and technology business management arm of the New World Group, one of Hong Kong's blue chip conglomerates. Comprising three operational areas - Telecom, Media and Technology - NWTMT invests and operates in innovative telemedia enterprises in China and the Asia Pacific region.
      New World TMT is positioned to benefit from regional liberalization initiatives and technological advancement. By way of providing management support, strategic partnerships and capital, the company aims to maximize returns and create shareholder value for a portfolio of enterprises in which NWTMT has significant equity interest.

    • Sequoia China

      The Sequoia team helps daring founders build legendary companies. In partnering with Sequoia, companies benefit from our unmatched community and the lessons we’ve learned over 46 years working with Apple, Cisco, Oracle, Google, Alibaba, Airbnb and JD.com among many others. As “The Entrepreneurs Behind The Entrepreneurs”, Sequoia China focuses on four sectors: TMT, healthcare, consumer/service, and industrial technology. Over the past 13 years we’ve had the privilege of working with more than 500 companies in China.

    • General Atlantic

      General Atlantic is a leading global growth equity firm providing capital and strategic support for growth companies. Established in 1980, General Atlantic combines a collaborative global approach, sector specific expertise, a long-term investment horizon and a deep understanding of growth drivers to partner with great entrepreneurs and management teams to build exceptional businesses worldwide. General Atlantic has more than 150 investment professionals based in New York, Amsterdam, Beijing, Greenwich, Hong Kong, Jakarta, London, Mexico City, Mumbai, Munich, Palo Alto, São Paulo, Shanghai, and Singapore. For more information on General Atlantic.

    ©Copyright-Adagene 2019